GlassScriptPhysician profile
Anushiravan Dadgar
NPI 1023066362
$10,787.92
in general payments reported to CMS, 2019-2025
63 companies · $1,522 in 2025
The $1,522 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,217 · 2020: $1,339 · 2021: $1,999 · 2022: $1,551 · 2023: $1,456 · 2024: $1,704 · 2025: $1,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,682.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,318.72 | 2020-2025 | Vraylar, Ubrelvy, Linzess |
| Novo Nordisk INC | $1,201.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $817.43 | 2019-2025 | Xifaxan |
| Pfizer INC. | $791.76 | 2020-2025 | |
| Lilly USA, LLC | $619.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $501.23 | 2021-2025 | Nexletol |
| Amgen INC. | $437.53 | 2019-2025 | Otezla, Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $381.51 | 2019-2025 | Trintellix |
| Allergan, INC. | $374.93 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $367.35 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $353.72 | 2019-2024 | |
| Glaxosmithkline, LLC. | $226.16 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $225.45 | 2020-2025 | Veozah |
| Gilead Sciences, INC. | $214.85 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $213.49 | 2019-2025 | Capvaxive, Pifeltro, Vaxneuvance |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anushiravan Dadgar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.